These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 21857531)
1. Infliximab in Crohn's disease-associated toxic megacolon. van Geenen EJ; Sachar DB J Clin Gastroenterol; 2012 Apr; 46(4):321-3. PubMed ID: 21857531 [TBL] [Abstract][Full Text] [Related]
2. Is really megacolon a contraindication to infliximab in Crohn's disease? Sinagra E; Orlando A; Renna S; Criscuoli V; La Seta F; Olivo M; Ciofalo M; Cottone M Acta Gastroenterol Belg; 2013 Dec; 76(4):442-4. PubMed ID: 24592552 [TBL] [Abstract][Full Text] [Related]
3. Fulminant Crohn's colitis: when only an antibody will do. Ng SC; Kamm MA Inflamm Bowel Dis; 2007 Aug; 13(8):971-4. PubMed ID: 17427240 [TBL] [Abstract][Full Text] [Related]
4. [Effect of infliximab in the treatment of refractory inflammatory bowel disease with complication]. Lee KM; Kim JS; Shin DH; Cheong JY; Yoo BM; Kim JK; Lee KJ; Hahm KB; Kim JH; Cho SW Korean J Gastroenterol; 2004 Nov; 44(5):259-66. PubMed ID: 15564805 [TBL] [Abstract][Full Text] [Related]
5. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340 [TBL] [Abstract][Full Text] [Related]
6. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease. de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M Digestion; 2008; 78(4):195-200. PubMed ID: 19122456 [TBL] [Abstract][Full Text] [Related]
7. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Vermeire S; Louis E; Carbonez A; Van Assche G; Noman M; Belaiche J; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Rutgeerts P; Am J Gastroenterol; 2002 Sep; 97(9):2357-63. PubMed ID: 12358256 [TBL] [Abstract][Full Text] [Related]
8. [Indications and results of infliximab in Crohn's disease]. Karoui S; Boubaker J; Filali A Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505 [TBL] [Abstract][Full Text] [Related]
9. Ustekinumab treatment for toxic megacolon in severe colonic Crohn's disease. Irabien M; Arreba P; Ortiz de Zárate J; Hernández-Aretxabaleta N; de la Maza-Ortiz S; Ispizua-Madariaga N; Muñoz-Villafranca C Rev Esp Enferm Dig; 2021 Mar; 113(3):189-192. PubMed ID: 33244975 [TBL] [Abstract][Full Text] [Related]
10. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study. Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720 [TBL] [Abstract][Full Text] [Related]
11. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated? Domènech E; Hinojosa J; Nos P; Garcia-Planella E; Cabré E; Bernal I; Gassull MA Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1107-13. PubMed ID: 16305724 [TBL] [Abstract][Full Text] [Related]
12. A case of hereditary hemorrhagic telangiectasia associated with Crohn's disease successfully treated with infliximab. Papa A; Felice C; Marzo M; Guidi L Am J Gastroenterol; 2010 Aug; 105(8):1904. PubMed ID: 20686472 [No Abstract] [Full Text] [Related]
13. Inflixmab as a possible treatment for the hemorrhagic type of Crohn's disease. Tsujikawa T; Nezu R; Andoh A; Saotome T; Araki Y; Ishizuka Y; Sasaki M; Koyama S; Fujiyama Y J Gastroenterol; 2004; 39(3):284-7. PubMed ID: 15065007 [TBL] [Abstract][Full Text] [Related]
14. [Infliximab therapy in children and adolescents with refractory Crohn's disease in the Netherlands; experience with 23 patients]. de Ridder L; Escher JC; Taminiau JA Ned Tijdschr Geneeskd; 2002 Oct; 146(40):1879-83. PubMed ID: 12395595 [TBL] [Abstract][Full Text] [Related]
15. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Ricart E; Panaccione R; Loftus EV; Tremaine WJ; Sandborn WJ Am J Gastroenterol; 2001 Mar; 96(3):722-9. PubMed ID: 11280541 [TBL] [Abstract][Full Text] [Related]
16. [Infliximab treatment of severe bleeding complicating Crohn's disease]. Julián Gómez L; Atienza R; Barrio J; Gil P; Gómez de la Cuesta S; Pinto P; Alcaide N; Caro Patón A Rev Esp Enferm Dig; 2010 Jan; 102(1):57-8. PubMed ID: 20187687 [No Abstract] [Full Text] [Related]
17. [Treatment of Crohn's disease with anti-TNF alpha antibodies (infliximab): results of a multicentric and retrospective study]. Doubremelle M; Bourreille A; Zerbib F; Heresbach D; Metman EH; Beau P; Gournay J; Galmiche JP Gastroenterol Clin Biol; 2002 Nov; 26(11):973-9. PubMed ID: 12483127 [TBL] [Abstract][Full Text] [Related]
18. The prevalence of malnutrition and the evolution of nutritional status in patients with moderate to severe forms of Crohn's disease treated with Infliximab. Vadan R; Gheorghe LS; Constantinescu A; Gheorghe C Clin Nutr; 2011 Feb; 30(1):86-91. PubMed ID: 20719413 [TBL] [Abstract][Full Text] [Related]
19. Crohn's-associated chronic recurrent multifocal osteomyelitis responsive to infliximab. Carpenter E; Jackson MA; Friesen CA; Scarbrough M; Roberts CC J Pediatr; 2004 Apr; 144(4):541-4. PubMed ID: 15069408 [TBL] [Abstract][Full Text] [Related]
20. Infliximab (Remicade), a new biological treatment for Crohn's disease. D'Haens GR Ital J Gastroenterol Hepatol; 1999; 31(6):519-20. PubMed ID: 10575573 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]